( A ) Data revealing GLP-1stimulated insulin secretion supported the approval of the first GLP-1RA for the treatment of T2D in 2005
GLP-1s have shown promise in improving blood sugar control in individuals with type 2 diabetes, which is often associated with weight gain
GLP-1 also inhibits the production of glucagon from the pancreas
Currently available GLP-1 receptor agonists include shorter-acting formulations such as exenatide (administered twice daily), daily options like liraglutide, and longer-acting agents like semaglutide and dulaglutide (weekly injections)
Who Might Benefit This approach is ideal for people who: Suspect MCAS or histamine intolerance React to multiple foods or medications Have digestive issues, bloating, or constipation Feel fatigued, anxious, or wired but tired Notice symptom flares after COVID-19 or other infections Have hormone or metabolic imbalances Havent found relief from standard antihistamines or low-histamine diets The Takeaway If your body feels constantly on edge reacting to food, stress, or your environment MCAS could be part of your story
Research shows Indians often develop type 2 diabetes at a BMI of 2325 a weight at which most Western medical guidelines wouldn't even consider screening for diabetes
